Skip to main content

Table 1 Demographic, clinical, laboratory characteristics and medication use of the total group of SLE patients and stratified for renal involvement

From: Neutrophil extracellular traps and oxidative stress in systemic lupus erythematosus patients with and without renal involvement

 

SLE (n = 100)

non-LN (n = 73)

LN (n = 27)

P-valuea

Gender, female

84 (84%)

62 (85%)

22 (81%)

0.760

Age, years

49 ± 11

50 ± 14

47 ± 14

0.443

Disease duration, years

11 (6–22)*

11 (6–21)*

12 (5–22)

0.829

BMI, kg/m2

25 (23–30)*

25 (23–29)*

26 (24–32)

0.419

Systolic blood pressure, mmHg

120 (110–137)

120 (110–139)

120 (110–130)

0.916

Diastolic blood pressure, mmHg

75 (70–80)

75 (70–80)

78 (70–80)

0.646

Alcohol

20 (20%)**

14 (19%)**

6 (22%)*

0.999

Smoking

25 (25%)**

20 (27%)**

5 (19%)*

0.306

Hypertension

21 (21%)*

15 (21%)

6 (22%)*

0.785

Diabetes

7 (7%)**

5 (7%)*

2 (7%)*

0.673

Obesity

27 (27%)*

16 (22%)*

11 (41%)

0.082

Laboratorial measurements

 Thrombocytes, 10^9/L

254 ± 72*

253 ± 78*

256 ± 54

0.972

 Hemoglobin, mmol/L

8.1 ± 0.9

8.2 ± 0.9

7.8 ± 0.8

0.037

 Lymphocytes total amount, 10^9/L

1.4 ± 0.6

1.4 ± 0.6

1.1 ± 0.4

0.016

 Neutrophils total amount, 10^9/L

4.1 (3.0–5.8)

4.1 (3.0–5.8)

3.9 (3.1–5.9)

0.795

 Leukocytes, 10^9/L

6.3 (4.7–8.0)

6.3 (4.9–8.1)

5.8 (4.6–7.4)

0.357

 C-reactive protein, mg/L

1.7 (0.7–5.0)*

2.0 (0.8–6.0)*

1.0 (0.4–3.3)

0.071

 eGFR, ml/min

87 ± 23

90 ± 21

79 ± 27

0.043

 Serum creatinine, µmol/L

73 (63–83)

70 (62–80)

78 (72–95)

0.011

 Albumin, g/L

43 (41–45)**

43 (41–45)**

43 (40–44)*

0.288

 Proteinuria positive

11 (11%)

3 (4%)

8 (30%)

0.001

 Proteinuria, if positive, g/24 h

0.59 (0.40–0.64)

0.40 (0.40–0.52)

0.60 (0.43–0.77)

0.442

 Cholesterol, mmol/L

4.3 (3.8–5.0)*

4.3 (3.7–4.8)*

4.6 (4.0–5.1)

0.188

 TG, mmol/L

1.4 (1.1–1.9)¶

1.2 (0.8–1.5)¶

1.7 (1.3–2.5)**

0.006

 LDL-C, mmol/L

2.5 (2.1–3.1)*

2.4 (2.0–3.0)*

2.6 (2.3–3.3)

0.143

 HDL-C, mmol/L

1.5 (1.2–1.8)*

1.5 (1.3–1.8)*

1.4 (1.1–1.9)

0.323

 ALAT, U/L

19 (14–27)

19 (14–28)

19 (15–26)

0.744

 anti-dsDNA titer, IU/mL

4 (1–13)

4 (1–11)

5 (1–19)

0.264

 Complement 3, g/L

1.03 (0.90–1.18)

1.02 (0.90–1.17)

1.07 (0.93–1.23)

0.834

 Complement 4, g/L

0.18 (0.13–0.23)

0.17 (0.13–0.23)

0.19 (0.14–0.24)

0.630

Medication use

 Hydroxychloroquine

80 (80%)

59 (81%)

21 (78%)

0.467

 Prednisolone

37 (37%)

21 (29%)

16 (59%)

0.005

 Aspirin

12 (12%)

9 (12%)

3 (11%)

0.587

 NSAID

24 (24%)*

23 (32%)*

1 (4%)

0.002

 ACE-I or ARB

33 (33%)

13 (18%)

20 (74%)

 < 0.001

 Azathioprine

14 (14%)

5 (7%)

9 (33%)

0.002

 Mycophenolate mofetil

14 (14%)

9 (12%)

5 (19%)

0.311

 Methotrexate

8 (8%)

8 (11%)

0

0.072

 Leflunomide

1 (1%)

1 (1%)

0

0.730

 Cyclophosphamide

2 (2%)

1 (1%)

1 (4%)

0.469

  1. Abbreviations: non-LN SLE without renal involvement, LN Lupus nephritis, BMI Body mass index, TG Triglyceride, eGFR Estimated glomerular filtration rate, LDL-C Low-density lipoprotein-cholesterol, HDL-C High-density lipoprotein-cholesterol, ALAT Alanine aminotransferase, NSAID Non-steroidal anti-inflammatory drugs, ACE-I Angiotensin-converting enzyme inhibitors, ARB Angiotensin receptor blockers, anti-dsDNA Anti-double stranded DNA
  2. arepresents comparison of patients with non-LN and LN
  3. Parameters are presented as mean ± SD, median (IQR) or number (%) of patients; Missing data * ≤ 7%, **7–17%, ¶ > 17%; Positive proteinuria is defined as > 0.3 g/24 h
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us